CalciMedica (CALC) Projected to Announce Quarterly Earnings on Wednesday

CalciMedica (NASDAQ:CALC) is projected to release its resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($1.2750) per share for the quarter.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.97. On average, analysts expect CalciMedica to post ($5.25) EPS for the current fiscal year and ($3.15) EPS for the next fiscal year.

CalciMedica Trading Down 2.0%

NASDAQ:CALC opened at $1.44 on Wednesday. The company’s 50 day moving average price is $1.70 and its 200-day moving average price is $4.01. CalciMedica has a 52 week low of $1.00 and a 52 week high of $36.00. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67. The stock has a market cap of $9.84 million, a price-to-earnings ratio of -0.21 and a beta of 0.84.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. UBS Group reissued a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Guggenheim began coverage on CalciMedica in a research note on Thursday, August 20th. They issued a “buy” rating for the company. Finally, Wall Street Zen cut shares of CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CalciMedica has a consensus rating of “Hold” and a consensus price target of $50.00.

CalciMedica Company Profile

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.